This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT04960709
Brief Title: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

First Submitted : June 17, 2021
First Submitted that Met QC Criteria : July 2, 2021
First Posted : July 14, 2021

Last Update Submitted that Met QC Criteria : January 24, 2024
Last Update Posted : January 25, 2024